Tag: Verzenio
-
Eli Lilly’s Inluriyo–Verzenio Combination Wins FDA Approval in ESR1-Mutated Breast Cancer
The FDA approved Eli Lilly’s Inluriyo plus Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. In an exploratory EMBER-3 analysis, median progression-free survival was 11.1 months with the combination versus 5.5 months with Inluriyo alone.